Affymetrix (AFFX) Sees Q3 Revs Below Consensus; Cites Cut Academic Funding
Tweet
Share
E-mailGet Alerts AFFX Hot Sheet
Price: $14.01 --0%
Financial Fact:
Total costs and expenses: 90.67M
Today's EPS Names:
DOYU, TWIN, FLO, More
Financial Fact:
Total costs and expenses: 90.67M
Today's EPS Names:
DOYU, TWIN, FLO, More
Join SI Premium – FREE
Affymetrix, Inc. (Nasdaq: AFFX) reported that based on preliminary financial data, the Company expects total revenue of approximately $80 million for the third quarter of 2012, with revenue of approximately $18 million from the eBioscience business. The Company expects to report cash-on-hand of approximately $39.6 million as of September 30, 2012, after a $3.5 million interest and principal payment on the Company’s senior debt.
The Street is currently sees revs of $84.6 million.
The Company believes that total revenue for the third quarter was negatively impacted by a tightening academic funding environment worldwide, primarily affecting its gene expression and eBioscience business units.
The Street is currently sees revs of $84.6 million.
The Company believes that total revenue for the third quarter was negatively impacted by a tightening academic funding environment worldwide, primarily affecting its gene expression and eBioscience business units.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ATRenew Inc (RERE) Tops Q2 EPS by 8c ; Offers Guidance
- Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
- Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
